Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong that it destroys healthy cells in the body. Checkpoint inhibitors are a type of immunotherapy. They block proteins that stop the immune system from attacking the cancer cells.
Cancer drugs do not always fit easily into a certain type of treatment. This is because some drugs work in more than one way and belong to more than one group.
Checkpoint inhibitors are also described as a type of monoclonal antibody or targeted treatment.
We would like to address the current research on the topic and also highlight new directions through the research process worldwide as it has become one of the lead pathways in combating cancer, with ovarian cancer being one of its forms and being the top killer in all female related cancers.
Papers submitted could be research articles, research letters or reviews that address work done so far but also shed light into new developments in the field of immune checkpoint in ovarian cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong that it destroys healthy cells in the body. Checkpoint inhibitors are a type of immunotherapy. They block proteins that stop the immune system from attacking the cancer cells.
Cancer drugs do not always fit easily into a certain type of treatment. This is because some drugs work in more than one way and belong to more than one group.
Checkpoint inhibitors are also described as a type of monoclonal antibody or targeted treatment.
We would like to address the current research on the topic and also highlight new directions through the research process worldwide as it has become one of the lead pathways in combating cancer, with ovarian cancer being one of its forms and being the top killer in all female related cancers.
Papers submitted could be research articles, research letters or reviews that address work done so far but also shed light into new developments in the field of immune checkpoint in ovarian cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.